Drug Profile
Research programme: cancer therapeutics - Ohara Pharmaceuticals
Alternative Names: OP-10 series; OP-12; OP-20 series; OP-21Latest Information Update: 28 Feb 2021
Price :
$50
*
At a glance
- Originator Ohara Pharmaceutical
- Class Antineoplastics; Aza compounds; Deoxyribonucleosides
- Mechanism of Action DNA methylation inhibitors; Methyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Colorectal cancer; Myelodysplastic syndromes
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for preclinical development in Myelodysplastic-syndromes in Japan
- 28 Dec 2020 No recent reports of development identified for preclinical development in Colorectal-cancer in Japan
- 10 Jan 2017 Preclinical trials in Myelodysplastic syndromes in Japan before January 2017 (Ohara Pharamceutical pipeline, January 2017)